Loading clinical trials...
Loading clinical trials...
High risk human papillomavirus (hr-HPV) persistent infection is a high risk factor for cervical cancer. 85% to 90% of hr-HPV infections have the ability to clear on their own, while 10% to 15% of HPV ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Peking University People's Hospital
NCT07407569 · Human Papilloma Virus Infection Type 16
NCT07450703 · Cancer , Healthy, HPV - Anogenital Human Papilloma Virus Infection, and more
NCT03638427 · HPV - Anogenital Human Papilloma Virus Infection
NCT05316064 · Human Papilloma Virus Infection
NCT05439083 · Human Papilloma Virus Infection
Peking University People's Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions